Skip to main content Skip to select language

Share information

Stock Price



 
 
 
 
 

Analyst coverage

Exane BNP Paribas

Giuseppe Grimaldi

E-mail: giuseppe.grimaldi@exanebnpparibas.com

CICC

Liwei Hou

E-mail: liwei.hou@cicc.com.cn

Kepler Chevreux

Niccolò Guido Storer

E-mail: nstorer@keplercheuvreux.com

Equita

Emanuele Gallazzi

E-mail: e.gallazzi@equita.eu

Berenberg

Anna Frontani

E-mail: anna.frontani@berenberg.com

Goldman Sachs

Louise Singlehurst

E-mail: louise.singlehurst@gs.com

Mediobanca

Gilles Errico

E-mail: gilles.errico@mediobanca.com

Mediobanca

Chiara Rotelli

E-mail: chiara.rotelli@mediobanca.com

JP Morgan

Chiara Battistini

E-mail: chiara.x.battistini@jpmorgan.com


IR Calendar

Date

Event

Link

19/02/2024

BOARD OF DIRECTORS
Approval of the preliminary consolidated results as at December 31, 2023

 

14/03/2024

BOARD OF DIRECTORS
Approval of the draft of the Financial Statement and the Consolidated Financial Statement as at December 31, 2023

 

22/04/2024

ANNUAL GENERAL MEETING OF SHAREHOLDERS
Approval of the Financial Statement as at December 31, 2023

 

16/05/2024

BOARD OF DIRECTORS
Approval of the Interim Financial Report as at March 31, 2024

 

29/08/2024

BOARD OF DIRECTORS
Approval of the Half-Year Financial Report as at June 30, 2024

 

13/11/2024

BOARD OF DIRECTORS
Approval of the Interim Financial Report as at September 30, 2024

Link Webinar

IR Calendar

Date

Event

Link

19/02/2024

BOARD OF DIRECTORS
Approval of the preliminary consolidated results as at December 31, 2023

 

14/03/2024

BOARD OF DIRECTORS
Approval of the draft of the Financial Statement and the Consolidated Financial Statement as at December 31, 2023

 

22/04/2024

ANNUAL GENERAL MEETING OF SHAREHOLDERS
Approval of the Financial Statement as at December 31, 2023

 

16/05/2024

BOARD OF DIRECTORS
Approval of the Interim Financial Report as at March 31, 2024

 

29/08/2024

BOARD OF DIRECTORS
Approval of the Half-Year Financial Report as at June 30, 2024

 

13/11/2024

BOARD OF DIRECTORS
Approval of the Interim Financial Report as at September 30, 2024